Want to see FR:DBV full AI Analyst Report?
Top Page
DBV Technologies
(DBV)
Select Model
Select Model
Rating:43Neutral
Price Target:
€2.00
▼(-15.61% Downside)
Action:Reiterated
Date:07/18/26
Overall score is pressured primarily by very weak financial performance driven by large ongoing losses and substantial cash burn, which implies continued financing reliance. Technicals add a secondary headwind with the stock trading below major moving averages and negative MACD. Valuation contributes modestly negative given the loss-making profile (negative P/E) and no dividend yield support in the provided data.
Positive Factors
Low leverage / solid balance sheet
Low absolute debt versus sizable equity materially reduces near-term solvency risk and gives the company strategic flexibility. For a clinical-stage biotech this balance-sheet strength lengthens runway for trials, licensing or partnership negotiations without immediate refinancing pressure.
Negative Factors
Large ongoing cash burn
Sustained, very large operating and free cash outflows create a structural financing requirement. Over months this erodes cash reserves, forces dilutive raises or debt, and constrains discretionary spending. For a pre-revenue biotech this materially raises execution and funding risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / solid balance sheet
Low absolute debt versus sizable equity materially reduces near-term solvency risk and gives the company strategic flexibility. For a clinical-stage biotech this balance-sheet strength lengthens runway for trials, licensing or partnership negotiations without immediate refinancing pressure.
Read all positive factors
DBV Technologies (DBV) vs. iShares MSCI France ETF (EWQ)
Market Cap
€746.19M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue GrowthN/A
EPS Growth41.33%
CountryFR
Employees170
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.77
Shares Outstanding314,375,400
10 Day Avg. Volume1,201,659
30 Day Avg. Volume1,025,603
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€3.59M
DBV Technologies Business Overview & Revenue Model
Company Description
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical...
How the Company Makes Money
null...
DBV Technologies Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.73M | 0.00 | 4.15M | 15.73M | 25.07M | 5.71M |
| Gross Profit | -7.00M | -18.34M | 4.15M | 15.73M | 4.77M | -3.57M |
| EBITDA | -166.19M | -140.58M | -109.05M | ― | -76.33M | -79.77M |
| Net Income | -176.26M | -152.94M | -113.92M | -72.73M | -96.27M | -97.81M |
Balance Sheet | ||||||
| Total Assets | 223.20M | 233.75M | 65.66M | 183.04M | 246.40M | 146.72M |
| Cash, Cash Equivalents and Short-Term Investments | 174.90M | 194.19M | 32.46M | 141.37M | 209.20M | 77.30M |
| Total Debt | 21.80M | 7.99M | 6.95M | 5.67M | 3.02M | 9.74M |
| Total Liabilities | 62.80M | 64.96M | 38.27M | 43.02M | 52.13M | 47.45M |
| Stockholders Equity | 160.50M | 168.79M | 27.39M | 140.19M | 194.50M | 99.27M |
Cash Flow | ||||||
| Free Cash Flow | -170.70M | -126.68M | -106.81M | -80.33M | -56.45M | -109.16M |
| Operating Cash Flow | -169.40M | -126.12M | -104.47M | -79.65M | -55.70M | -108.24M |
| Investing Cash Flow | -1.86M | -1.42M | -757.00K | -786.62K | -100.00K | -433.00K |
| Financing Cash Flow | 248.19M | 287.44M | 587.00K | 6.77M | 194.10M | 274.00K |
DBV Technologies Technical Analysis
Negative
2.37
Price Trends
2.58
Negative
2.92
Negative
3.14
Negative
Market Momentum
-0.03
Negative
41.77
Neutral
19.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DBV, the sentiment is Negative. The current price of 2.37 is below the 20-day moving average (MA) of 2.44, below the 50-day MA of 2.58, and below the 200-day MA of 3.14, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.77 is Neutral, neither overbought nor oversold. The STOCH value of 19.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:DBV.
DBV Technologies Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €870.42M | -26.42 | ― | ― | -23.21% | -50.69% | |
53 Neutral | €205.98M | -3.24 | 593.93% | ― | -77.92% | 11.11% | |
47 Neutral | €222.34M | -3.04 | -63.53% | ― | 291.43% | 12.24% | |
47 Neutral | €513.56M | -3.12 | -152.15% | ― | -27.19% | -117.39% | |
43 Neutral | €746.19M | -3.49 | -119.47% | ― | ― | 41.33% | |
33 Underperform | €75.67M | -1.89 | -96.73% | ― | -96.25% | -197.89% |
* General Sector Average
FR:DBV
DBV Technologies
2.32
0.78
51.08%
FR:IPH
Innate Pharma SA
1.78
-0.06
-3.36%
FR:TNG
Transgene
0.79
-0.31
-28.51%
FR:VLA
Valneva
2.81
-0.67
-19.32%
FR:OSE
OSE Immunotherapeutics SA
3.20
-2.99
-48.33%
FR:MEDCL
MedinCell SA
24.04
7.12
42.08%
DBV Technologies Corporate Events
DBV Technologies Raises $50 Million via Nasdaq ATM Share Sale
Jul 30, 2026
DBV Technologies has raised approximately $50 million through the sale of new American Depositary Shares on Nasdaq under its at-the-market program, issuing 18,288,220 new ordinary shares underlying 3,657,644 ADSs to RA Capital Management via Citiz...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.